Annovis Bio (NYSE:ANVS – Get Free Report) and Roivant Sciences (NASDAQ:ROIV – Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, institutional ownership, risk and earnings.
Earnings and Valuation
This table compares Annovis Bio and Roivant Sciences”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Annovis Bio | N/A | N/A | -$56.20 million | ($4.46) | -1.21 |
| Roivant Sciences | $129.13 million | 65.90 | $4.35 billion | $5.65 | 2.07 |
Roivant Sciences has higher revenue and earnings than Annovis Bio. Annovis Bio is trading at a lower price-to-earnings ratio than Roivant Sciences, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Annovis Bio | 0 | 1 | 4 | 1 | 3.00 |
| Roivant Sciences | 0 | 1 | 7 | 0 | 2.88 |
Annovis Bio presently has a consensus target price of $31.40, indicating a potential upside of 482.56%. Roivant Sciences has a consensus target price of $17.93, indicating a potential upside of 53.37%. Given Annovis Bio’s stronger consensus rating and higher probable upside, equities analysts clearly believe Annovis Bio is more favorable than Roivant Sciences.
Risk and Volatility
Annovis Bio has a beta of 1.59, meaning that its share price is 59% more volatile than the S&P 500. Comparatively, Roivant Sciences has a beta of 1.25, meaning that its share price is 25% more volatile than the S&P 500.
Insider & Institutional Ownership
15.8% of Annovis Bio shares are held by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are held by institutional investors. 32.3% of Annovis Bio shares are held by insiders. Comparatively, 7.9% of Roivant Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Profitability
This table compares Annovis Bio and Roivant Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Annovis Bio | N/A | -876.22% | -311.00% |
| Roivant Sciences | 3,827.42% | -14.65% | -13.19% |
Summary
Roivant Sciences beats Annovis Bio on 9 of the 14 factors compared between the two stocks.
About Annovis Bio
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.
About Roivant Sciences
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.
Receive News & Ratings for Annovis Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Annovis Bio and related companies with MarketBeat.com's FREE daily email newsletter.
